Collaborations: researching a cure at the sub-cellular level for a wide-range of ROS-based disorders

Exscien Corporation holds the exclusive license to discoveries originating at the University of South Alabama and subsequent research partnerships with leading institutions worldwide. Our discoveries have led to the reversal of cellular damage and increased cell vitality with a uniquely synthesized and patented multi-part fusion protein that mitigates oxidative stresses to mitochondrial DNA. Examples of collaborative studies:

Related to mtDNA repair during stroke reperfusion to reduce brain damage:
Drs. Simon, McGuire and Wilson, Neuroscience Institute, Morehouse School of Medicine. Working to develop therapeutic strategies based on application of the fusion protein directed at acute stroke, in particular the inhibition of reactive oxygen species (ROS). Decades of laboratory and clinical studies make it clear that ROS are pathogenically important across the entire spectrum of cerebrovascular disease.

Related to the growth and metastasis of breast cancer tumors:
Drs. Ming Tan, M.D., Ph.D., Assoc. Professor, Oncological Sciences and Luda Rachek, Ph.D., Assoc. Professor, Cell Death and Metabolism Research Center, Mitchell Cancer Institute. Their initial studies in rodent models have revealed that the fusion protein has been able to retard the growth of breast cancer cells and stop their metastasis.

Related to the use of the fusion protein in the setting of cardiovascular disease:
DR. Lefer, LSU Health Sciences Center, New Orleans, LA, Professor, Department of Pharmacology in the School of Medicine at the LSU Health Sciences Center, Director, Cardiovascular Center of Excellence at the LSU Health Sciences Center. Dr. Lefer supervises a research program that focuses on the investigation of cardioprotection in the setting of cardiovascular disease with an emphasis on acute myocardial infarction and congestive heart failure.Dr. Lefer is currently investigating the use of Exscien’s protein as repair-based therapies for heart failure with a number of studies involving various preclinical translational model systems.

Related to the impact of the fusion protein on the vitality of ransplanted islet cells, as well as the preservation of liver and kidneys for transplantation:
Dr. Louis Fernandez, specializes in pancreas, liver, islet cell and renal transplantation, and is a researcher and transplant surgeon at the University of Wisconsin School of Medicine and Public Health. Use of Exscien’s fusion protein for the preservation of nonpulmonary organs used in transplant.

Related to the use of the fusion protein to mitigate mtDNA damage-associated molecular pattern molecules (DAMPs) in traumatic injury:
Drs.Simmons, Lee, Mulekar, Kuck, Brevard, Gonzalez, Gillespie and Richards, University of South Alabama Medical Center and College of Medicine. Elevated levels of plasma mitochondrial DNA DAMPs were able to be linked to clinical outcomes in severely injured human subjects. The combination of DNASE1 and the fusion protein is being examined to mitigate the effects of trauma.

Related to sepsis and multi-organ system failure:
Col. Matthew Martin, M.D., Madigan Army Medical Center, Tacoma Washington. Dr. Martin is the Trauma Medical Director and Chief of Surgical Critical Care at Madigan. Multiple organ system failure is a significant complication of severe illness or injury. Isolated pharmacologic targets for prevention or reversal of this syndrome have yet to be identified. Since oxidant stress plays an important pathogenic role in multi-organ system failure, Exscien’s fusion protein was tested and found successful in fully suppressing organ dysfunction in an intact rat model of induced sepsis.

Related to porcine models to test the safety and efficacy of the fusion protein for lung transplants:
Drs. Beaver and Machuca, cardiothoracic and lung transplant surgeons the University of Florida College of Medicine. Drs. Beaver and Machuka have considerable developmental and published experience with the use of porcine models of in vivo lung injury followed by ex vivo perfusion and lung transplant. Exscien’s fusion protein is being tested for safety and efficacy in these settings.

Related to the use of the fusion protein as a perfusion fluid for lung transplants:
Drs. Zamora and Weyant, a transplant pulmonologist and cardiothoracic surgeon, respectively, from the University of Colorado Medical Center. Drs. Zamora and Weyant have an impressive history in terms of their contribution to gaining FDA approval for the first ex vivo lung perfusion device and relative to their involvement in a number of clinical trials on primary graft dysfunction and lung transplant rejection.